This clinical trial is for men and women ages 18 and older with follicular lymphoma with detectable BCL2 translocation or mantle cell lymphoma with presence of cyclin D1 overexpression. The objective of this study is to assess the possibility of treating follicular lymphoma and mantle cell lymphoma patients with ribavirin and using cell free DNA (cfDNA) for BCL2-t and cyclin D1 extracted from peripheral blood to measure treatment effect.
More information on this trial: Weill Cornell Medicine New York Presbyterian Hospital Joint Clinical Trials Office https://jcto.weill.cornell.edu
Related research:
1. Sarah C. Rutherford, Eric N. Stewart, Zhengming Chen, Amy Chadburn, Natasha E. Wehrli, Koen van Besien, Peter Martin, Richard R. Furman, John P. Leonard & Leandro Cerchietti (2017) The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data, Leukemia & Lymphoma, 59:1, 256-258, DOI: 10.1080/10428194.2017.132327
2. Culjkovic-Kraljacic, B., Fernando, T. M., Marullo, R., Calvo-Vidal, N., Verma, A., Yang, S., Tabbò, F., Gaudiano, M., Zahreddine, H., Goldstein, R. L., Patel, J., Taldone, T., Chiosis, G., Ladetto, M., Ghione, P., Machiorlatti, R., Elemento, O., Inghirami, G., Melnick, A., Borden, K. L., & Cerchietti, L. (2016). Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood, 127(7), 858-868.https://doi.org/10.1182/blood-2015-05-64506
3. Yeomans, A., & Packham, G. (2016). Shooting the messenger (RNA) in B-cell lymphoma. Blood, 127(7), 794-796. https://doi.org/10.1182/blood-2015-12-685156.